Cancer Therapy

Strong results from Australian cancer vaccine trials

Published in Cancer Weekly, December 17th, 2002

Australian Cancer Technology, Ltd. (AustCancer) (ACU) has announced achievement of a major milestone in phase Ib/IIa clinical trials of its Pentrix anticancer vaccine at St Vincent's Hospital, Sydney.

The results will enable the company to proceed to the next stage of development of Pentrix, which is a potentially important treatment in the fight against cancer.

Pentrix is an "anti-idiotypic" (molecular mimic technology) vaccine that is intended to induce the body's immune system to attack tumors. All five patients who have completed the multidose trial to date have produced a strong immune response, giving the first indications of the potential...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2002-12-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry